Collagen Scaffold Helps Starved Tumours Switch Fuel and Evade Treatment

Cancer cells are notoriously adaptable, and one of the most striking examples of that adaptability has now been pinned down at the molecular level. New research from the University of Sheffield shows that tumours surrounded by dense, scar-like tissue can survive conditions that should starve them to death, by exploiting a surprisingly ordinary component of the human body: type I collagen. The finding, published in PLOS Biology and funded by Cancer Research UK, suggests that blocking this collagen-driven survival mechanism could slow tumour growth and make existing therapies such as chemotherapy work better at lower, less toxic doses.

The study, led by Dr Elena Rainero, a Senior Lecturer at the University of Sheffield and based at the Sheffield Centre for Cancer Research, focused on two of the most aggressive and hard-to-treat cancers: breast cancer and pancreatic cancer. Both are characterised by tumours encased in a thick protective scaffold of connective tissue known as the extracellular matrix. In these cancers, this scaffolding is no minor component of the disease. It can make up as much as 90 per cent of the tumour’s total mass, forming a dense, fibrous barrier that severely restricts the blood vessels running through it.

That restriction has long posed a biological puzzle. Blood supply delivers glucose, the primary source of energy for cells in the body, along with the oxygen and nutrients that growing tissue requires. If a tumour’s scaffold chokes off that supply, the cancer cells inside should, in principle, be starved of fuel and die. Clinically, however, these nutrient-deprived tumours do not die. They persist, adapt, and often become more difficult to treat, spreading to other organs and taking root there. The Sheffield team set out to explain how.

The answer they uncovered centres on type I collagen, the most abundant protein in the human body and a major structural building block of the scaffolding that surrounds tumours. Rather than serving as passive scaffolding, the study found that this collagen actively participates in tumour survival. When glucose levels around the cancer cells drop, the collagen triggers signalling that allows the cells to switch to an alternative fuel supply: essential amino acids, the molecular building blocks that cancer cells need to construct the proteins required for growth and division.

The switch depends on a transporter protein called LAT1, which the researchers describe as functioning like an internal delivery system. LAT1 sits in the membrane of the cancer cell and pulls amino acids from outside the cell into its interior, sustaining the tumour through periods when its usual energy source is unavailable. In effect, the dense tissue that physically walls a tumour off from the bloodstream also provides the chemical signal that allows the tumour to change its diet and keep growing.

Laboratory tests on cellular models demonstrated that this vulnerability can be attacked. When the researchers blocked LAT1 transporters and simultaneously interrupted the cancer cells’ interaction with the surrounding collagen, the cells were cut off from the amino acids they had been importing and were starved of vital nutrients. That combined intervention offers a promising target for future therapies, particularly because it addresses a survival mechanism rather than the tumour cells themselves, which are prone to evolving resistance against direct attacks.

The clinical implications of the discovery extend beyond simply finding a new drug target. Dr Rainero noted that because cancer cells adapt so quickly, single treatments rarely eradicate a tumour entirely. Blocking the collagen-driven survival mechanism, she explained, could slow the growth and spread of cancer cells while making them more sensitive to existing treatments such as chemotherapy. A tumour that cannot switch fuel sources is a tumour under far greater metabolic stress, and one that standard therapies may finish off more effectively.

That sensitising effect could, in turn, allow clinicians to lower the doses of chemotherapy they administer. Dose reduction is far from a trivial benefit: severe and debilitating side effects are among the most burdensome aspects of cancer treatment, and lowering the amount of drug a patient receives while maintaining or improving effectiveness would meaningfully reduce that burden. According to the Sheffield team, the ultimate goal is to combine interference with the collagen-LAT1 pathway with existing therapies, starving aggressive tumours, stopping them from spreading, and preventing them from taking root elsewhere in the body, all with less toxic treatment regimens.

Scientifically, the study adds to a growing recognition that the tumour microenvironment is not merely background scenery but an active participant in cancer progression. The extracellular matrix, long studied for its physical role in blocking drug delivery and immune cell access, now appears to supply metabolic cues as well. Understanding how structural proteins such as type I collagen send signals that reprogramme cancer cell metabolism opens a new line of investigation into how tumours cope with the nutrient-poor conditions that their own growth creates, and why nutrient deprivation alone has so often failed as a therapeutic strategy.

The research, titled Collagen I promotes cancer cell survival via amino acid import and mTORC1/S6 activation, was published in PLOS Biology on 18 September 2026. As an observational study conducted on cells, it now awaits the translational work that will determine whether blocking LAT1 and disrupting collagen interactions can be achieved safely and effectively in patients. For cancers such as pancreatic ductal tumours, where treatment options remain limited and survival rates remain stubbornly poor, a strategy that turns the tumour’s own protective scaffold into a liability represents one of the more compelling new directions in cancer research.

Subject of Research: How type I collagen in the extracellular matrix helps breast and pancreatic cancer cells survive nutrient deprivation by switching to amino acid uptake via LAT1

Article Title: Starving cancer’s fuel source could boost treatment effectiveness

Article References: Starving cancer’s fuel source could boost treatment effectiveness. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cancer, type I collagen, extracellular matrix, LAT1, amino acid transport, pancreatic cancer, breast cancer, metabolism, chemotherapy, tumour microenvironment, University of Sheffield, PLOS Biology